JAMA Network
About The Study: In this randomized clinical trial of 3,777 patients with ST-segment elevation myocardial infarction (STEMI; a type of heart attack), the Chinese patent medicine Tongxinluo, as an adjunctive therapy in addition to STEMI guideline-directed treatments, significantly improved both 30-day and 1-year clinical outcomes. Further research is needed to determine the mechanism of action of Tongxinluo in STEMI.
Authors: Yuejin Yang, M.D., Ph.D., and Runlin Gao, M.D., of the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.19524)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
